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Background. We investigated changes in hepatic fibrosis, based on transient elastography (TE), among human immunode-
ficiency virus (HIV)–infected patients with and without hepatitis B virus (HBV) coinfection on antiretroviral therapy (ART) in 
Zambia.
Methods. Patients’ liver stiffness measurements (LSM; kiloPascals [kPa]) at ART initiation were categorized as no or minimal 
fibrosis (equivalent to Metavir F0–F1), significant fibrosis (F2–F3), and cirrhosis (F4). TE was repeated following 1 year of ART. 
Stratified by HBV coinfection status (hepatitis B surface antigen positive at baseline), we described LSM change and the proportion 
with an increase/decrease in fibrosis category. Using multivariable logistic regression, we assessed correlates of significant fibrosis/
cirrhosis at 1 year on ART.
Results. Among 463 patients analyzed (61 with HBV coinfection), median age was 35 years, 53.7% were women, and median 
baseline CD4+ count was 240 cells/mm3. Nearly all (97.6%) patients received tenofovir disoproxil fumarate–containing ART, in 
line with nationally recommended first-line treatment. The median LSM change was −0.70 kPa (95% confidence interval, −3.0 to 
+1.7) and was similar with and without HBV coinfection. Significant fibrosis/cirrhosis decreased in frequency from 14.0% to 6.7% 
(P < .001). Increased age, male sex, and HBV coinfection predicted significant fibrosis/cirrhosis at 1 year (all P < .05).
Conclusion. The percentage of HIV-infected Zambian adults with elevated liver stiffness suggestive of significant fibrosis/cir-
rhosis decreased following ART initiation—regardless of HBV status. This suggests that HIV infection plays a role in liver inflamma-
tion. HBV-coinfected patients were more likely to have significant fibrosis/cirrhosis at 1 year on ART.
Clinical Trials Registration. NCT02060162.
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Among human immunodeficiency virus (HIV)–infected indi-
viduals, liver-related mortality is primarily attributed to viral 
hepatitis coinfection [1]. However, HIV infection also induces 
hepatic inflammation and immune activation, and unsup-
pressed HIV infection is a risk factor for liver fibrosis progres-
sion [2–5]. The World Health Organization (WHO) and most 
national guidelines recommend that HIV–hepatitis B virus 
(HBV)–coinfected individuals receive an antiretroviral ther-
apy (ART) regimen that contains tenofovir disoproxil fumarate 
(TDF) because the drug is highly potent against both viruses 
[6, 7]. Among HIV-negative individuals with chronic HBV 
infection (CHB), TDF not only suppressed HBV replication 
but also improved liver histology [8]. Among TDF-treated CHB 
patients in China, a biphasic pattern of fibrosis regression was 
described, reflected in both liver histology and transient elas-
tography (TE), a noninvasive surrogate of fibrosis/cirrhosis [9].
We sought to describe the impact of HBV-active ART on liver 
stiffness in a prospective HIV cohort study in Zambia, includ-
ing a subset of individuals with HIV–HBV coinfection. We 
hypothesized that liver stiffness, based on TE, would decrease 
in the year following ART initiation, particularly among those 
with HIV–HBV coinfection. Among HIV–HBV patients, we 
also aimed to establish the short-term HBV virological and 
serological outcomes of TDF-containing ART.
METHODS
IeDEA Hepatitis Cohort in Zambia
We established a prospective cohort of HIV-infected adults at 
2 public sector outpatient primary care facilities in Zambia’s 
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capital Lusaka under the framework of the International 
Epidemiologic Databases to Evaluate AIDS (IeDEA) collabo-
ration in southern Africa [10]. Any HIV-infected patient aged 
18+ years, treatment-naive, and eligible to initiate ART under 
national guidelines met the criteria to join the cohort [11]. The 
preferred first-line ART regimen consisted of the fixed-dose 
combination TDF, emtricitabine (FTC), and efavirenz (EFV), 
with abacavir, lamivudine, nevirapine (NVP) and ritona-
vir-boosted lopinavir as alternative agents. Baseline was defined 
as the time of ART initiation, and cohort characteristics at 
baseline were previously described [12, 13]. The University of 
Zambia (Lusaka) and University of North Carolina at Chapel 
Hill ethics committees approved this study. 
Study Procedures and Definitions
At baseline, we measured alanine aminotransferase (ALT; normal 
was <19 U/L for women and <30 for men), creatinine, and CD4+ 
count; tested for HBV and hepatitis C virus (HCV) coinfection; 
assessed alcohol consumption levels; and performed TE. HBV 
coinfection was defined as a positive hepatitis B surface antigen 
(HBsAg) test by finger prick (Determine, Alere, Waltham, MA) 
or in serum (Access2Analyzer, Beckman Coulter, Brea, CA); 
among those who were HBsAg positive, we measured serum hep-
atitis B e-antigen and HBV viral load (VL; COBAS AmpliPrep/
COBAS Taqman HBV test, version 2.0, Roche Molecular 
Systems, Pleasanton, CA). We used Sanger sequencing to deter-
mine HBV genotypes [14] and screened HIV–HBV patients for 
hepatitis delta antibodies (ETI-AB-Delta-2, Diasorin, Brussels, 
Belgium). We used a rapid point-of-care antibody test for HCV 
testing (OraQuick, OraSure Technologies, Bethlehem, PA) and 
confirmed active infections by measuring HCV RNA in antibody 
positives [12]. We used the Alcohol Use Disorders Identification 
Test–Consumption (AUDIT–C) questions to establish alcohol 
consumption levels and defined hazardous drinking as AUDIT–C 
score ≥3 for women and ≥4 for men [15–17]. We measured liver 
stiffness (in kiloPascals) using TE (Fibroscan 402, Echosens, 
Paris, France) in nonpregnant patients according to the manu-
facturer’s guidelines [18, 19]. Fasting was not required before TE; 
however, study visits occurred in the mid-morning or early after-
noon, and most patients had waited 1–4 hours without eating 
before the procedure. TE measurements were considered very 
reliable if the interquartile range divided by median (IQR/M) was 
<0.1, reliable if IQR/M was 0.1–0.3, and poorly reliable if IQR/M 
was >0.3 [20].
Follow-up visits for routine ART monitoring occurred at 2, 
4, 8, and 12 weeks and every 3 months thereafter. At 1 year on 
ART, we repeated baseline measurements with the exception of 
HCV testing and, in addition, assessed ART adherence using the 
medication possession ratio (MPR) [21]. MPR was categorized 
as optimal (>95%), suboptimal (80%–95%), and poor (<80%). 
During follow-up, deaths were ascertained by report of the 
patient’s family/friend, the clinic staff, or a community health 
worker. Transfers to other clinics were documented when a 
patient informed the staff of their intent to establish HIV care at 
a distant site. We considered a patient lost to follow-up (LTFU) 
if there were no documented clinical or pharmacy visits for at 
least 6 months and no 1-year visit.
Study Outcomes
Our primary outcome was change in hepatic stiffness based 
on TE. We categorized each liver stiffness measurement (LSM) 
according to its equivalent Metavir liver fibrosis stage as no/
minimal fibrosis (F0–F1), significant fibrosis (F2–F3), and cir-
rhosis (F4). This was done using thresholds that were previously 
established in published comparisons between TE and liver his-
tology. For patients with only HIV, no/minimal fibrosis was LSM 
<7.1 kPa, significant fibrosis was 7.1–11.0 kPa, and cirrhosis was 
≥11.1 kPa [22]. Among HIV–HBV patients, no/minimal fibrosis 
was <5.9 kPa, significant fibrosis was 5.9–9.3 kPa, and cirrhosis 
was ≥9.4 [23]. In HIV–HBV patients, we defined HBV virologi-
cal suppression (VS) as a VL <20 IU/mL. In mid-2014, Zambian 
national treatment guidelines incorporated routine HIV VL 
monitoring; therefore, a subset of the cohort participants also 
had an HIV VL at 1 year on ART (Roche COBAS AmpliPrep/
COBAS Taqman HIV-1 test, version 2.0, Pleasanton, California). 
HIV VS was defined as a VL <40 copies/mL.
Statistical Analyses
We excluded from analysis patients without TE at baseline. 
Among those with baseline TE, we further excluded those 
who died, transferred out, withdrew, became pregnant, or were 
LTFU, as well as those without a repeat TE at 1 year. We com-
pared the demographic and clinical characteristics of partici-
pants analyzed at the primary outcome with those excluded 
using the Wilcoxon rank-sum test for continuous variables 
and the χ2 test for categorical ones. In the analysis cohort, we 
compared baseline characteristics of patients with only HIV 
and those with HIV–HBV using the same tests. We graphed the 
distribution of fibrosis stages at baseline and 1 year and we ana-
lyzed the proportion who experienced a reduction in fibrosis 
using a McNemar test. In bivariable analyses, we considered the 
following potential correlates of liver fibrosis: age, sex, WHO 
stage, initial CD4+ count, body mass index, baseline ALT level, 
HBsAg positivity, HIV VS at 1 year, and hazardous alcohol con-
sumption at 1 year. A stepwise logistic regression model was 
used to identify factors associated with significant fibrosis or 
cirrhosis (F2–F4) at 1 year with backward selection algorithm. 
The probability of removal was set at 0.2 using likelihood ratio 
test. As HIV VS was an important possible risk factor, we main-
tained that variable in the final model.
Among the subset with HIV–HBV coinfection, we described 
the efficacy of ART to suppress HBV replication as the median 
log10 change in HBV VL and the percentage of coinfected indi-
viduals with VS at 1 year. In bivariable analyses, we explored 
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possible correlates of HBV VS including pretreatment HBV VL, 
HBeAg positivity, MPR, and HIV VS.
RESULTS
Cohort Characteristics
From October 2013 to August 2014, 798 eligible HIV-infected 
adults were enrolled in our cohort. Of these, 45 (5.6%) died, 19 
(2.4%) withdrew or transferred to another facility, and 38 (4.8%) 
were LTFU during the first year on ART. In addition, 29 women 
were pregnant at either baseline or 1-year visits and could not 
undergo TE. Of the remaining 667 retained to the 1-year visit, 
463 (69.4%) had valid TE at both time points and comprised 
the analysis cohort (Figure  1). Patients without TE (n  =  204) 
were similar to those analyzed in terms of their median age (35 
vs 35 years; P = .96) and percentage women (53.7% vs 53.8%; 
P = .98) but had slightly lower baseline CD4 counts (204 vs 240 
cells/mm3; P = .03) and higher prevalence of WHO stage 3 or 4 
(47.4% vs 36.6%; P = .01).
Within the analysis cohort (n = 463), 61 (13.2%) had HBV 
and none had active HCV coinfection (Table  1). HIV–HBV-
coinfected individuals were more likely to have hazardous alco-
hol consumption and had higher baseline ALT levels and LSM 
compared to those with only HIV (Table 1). Nearly all patients 
(97.6%) received fixed-dose combination TDF, FTC, and EFV. 
MPR (ie, ART adherence) at 1 year was optimal for 404 (89.8%), 
suboptimal for 34 (7.6%), and poor for 12 (2.7%). CD4+ counts 
increased by a median of 106 cells/mm3 (IQR, 33–199) from 
baseline to 1  year. HIV VL was available at 1  year for 301 
(65.0%) patients, and 253 (81.6%) were suppressed. HIV VS was 
observed in 84.1% of patients with optimal 1-year MPR, 66.7% 
with suboptimal, and 25.0% with poor adherence.
Change in Liver Stiffness
The median time between baseline and 1-year TE was 
11.7  months (95% confidence interval, 11.1–12.6). Most TE 
measurements were either very reliable (n = 450; 48.6%) or reli-
able (n = 469; 50.6%) and very few were poorly reliable (n = 7; 
0.8%). The median change in LSM was –0.70 kPa (IQR, –1.50 to 
+0.30) and was similar between patients with and without HBV 
coinfection (–0.7 vs –0.7 kPa; Figure 2). There was a significant 
reduction in the proportion with TE suggestive of significant 
fibrosis (14.0% vs 6.7%; P <  .001) or cirrhosis (2.2% vs 1.1%; 
P = .01). Among patients with only HIV, the finding of signifi-
cant fibrosis decreased from 9.2% to 4.5% (P = .002) while the 
finding of cirrhosis remained consistent (1.2% vs 1.0%; P = .10). 
For HIV–HBV-coinfected patients, a larger absolute reduction 
was observed for both significant fibrosis (45.9% vs 21.3%; 
P = <.001) and cirrhosis (8.2% vs 1.6%; P =  .04). Among the 
65 participants with F2–F4 at baseline, 46 (70.8%) experienced 
a reduction of liver fibrosis by 1 year on ART (Supplementary 
Table 1). Those with only HIV appeared more likely to experi-
ence a reduction compared to HIV–HBV-coinfected patients, 
but this association was not statistically significant (78.4% vs 
60.7%; P = .12). Other patient factors including age, sex, CD4+ 
count, baseline ALT, hazardous drinking at 1 year, and HIV VS 
were not associated with a change in fibrosis (Supplementary 
Table 2), although the numbers in each group were small.
Correlates of Significant Fibrosis/Cirrhosis at 1 Year on ART
In multivariable analysis, men (adjusted odds ratio [AOR], 
3.13; 95% CI, 1.10–8.93) and patients with HBV coinfection 
(AOR, 7.72; 95% CI, 2.89–20.57; Table 2) were more likely to 
have significant fibrosis/cirrhosis. With each 10-year increase 
in age there was an increased odds of the outcome (AOR, 1.81; 
95% CI, 1.07–3.07). HIV VS by 1 year was not associated with 
reduced odds of significant fibrosis/cirrhosis (AOR, 0.89; 95% 
CI, 0.26–3.04). Neither HBV VL nor HBV genotype (A1 vs E) 
were associated with 1-year LSM among coinfected patients. 
During follow-up there were 12 patients (2.6%; 10 with only 
HIV alone and 2 with HIV–HBV) who experienced progression 
to a higher disease category.
HBV Virological and Serological Outcomes
HIV–HBV patients also achieved significant virological con-
trol of HBV during the first year of ART. Among the 61 coin-
fected individuals, baseline HBV VL was available for all and 
1-year VL was available for 51 (83.6%). Median baseline HBV 
VL was 3.7 log10 IU/mL and 27 (44.3%) had HBV VL >4.3 log10 
IU/mL (20 000 IU/mL; Table 1). HBV genotypes were A1 for 
17 and E for 22 among the successfully sequenced samples. 
Figure 1. Cohort flow diagram. Abbreviations: ART, antiretroviral therapy; HBV, 
hepatitis B virus; HIV, human immunodeficiency virus; LTFU, lost to follow-up; TE, 
transient elastography.
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Nineteen were HBeAg positive, 34 were HBeAg negative, and 
the HBeAg status was not determined in 8 patients. Hepatitis 
delta antibodies were observed in 2 individuals. Following 
1 year of ART, HIV–HBV-coinfected patients with baseline 
detectable HBV DNA experienced a median reduction in 
HBV VL of 4.8 log10 IU/mL and 33 (64.7%) achieved HBV VS 
(Supplementary Figure 1). HBV VS at 1 year was more com-
mon among patients with optimal adherence compared to 
those with suboptimal/poor adherence (76.5% vs 11.8%; P = 
.08). HBeAg-positive patients were less likely to have HBV VS 
(31.3% vs 79.3%; P = .001). There was a trend toward lower 
HBV VL in patients with HIV VS compared to those with 
detectable HIV RNA at 1 year (1.0 vs 0.5 log10 IU/mL; Figure 3), 
but this did not reach statistical significance (P = .25). Among 
those who were HBeAg positive, 1 of the 14 retested (7.1%) 
experienced an HBeAg loss. Of 58 patients with an available 
HBsAg at baseline and 1 year, 7 (12.1%) became HBsAg nega-
tive. Although the absolute numbers were small, patients with 
HBsAg loss tended to be female (71.4% vs 43.1%) and slightly 
younger (median age 28.4 vs 36.4 years) compared to those 
who remained HBsAg positive. 
DISCUSSION
During the first year of ART in Zambia, the percentage of HIV-
infected Zambian adults with elevated liver stiffness suggestive 
of significant fibrosis/cirrhosis decreased following ART initi-
ation—regardless of HBV status. This suggests that HIV infec-
tion plays a role in liver inflammation. HIV–HBV patients had 
a good early viral response to ART; however, this group contin-
ued to have higher levels of liver fibrosis markers at 1 year on 
therapy. These data support recommendations for HBsAg test-
ing, early ART initiation, and close monitoring of liver disease 
in this at-risk group.
Our results provide further evidence of the benefits of 
effective ART on virological and clinical outcomes in HIV 
and HIV–HBV coinfection, especially regimens that contain 
potent HBV activity such as that provided by TDF. In line 
with previous reports from Europe and Africa, we observed 
Figure 2. Change in liver stiffness during the initial year of antiretroviral therapy among human immunodeficiency virus–infected adults in Zambia, by hepatitis B virus 
coinfection status. Abbreviations: HBV, hepatitis B virus; HIV, human immunodeficiency virus.
Table  1. Baseline Characteristics of Human Immunodeficiency Virus–
Infected Individuals Retained in Care for 1 Year on Antiretroviral Therapy 
in Lusaka, Zambia, by Hepatitis B Virus Coinfection Status
Characteristic
HIV Alone
(n = 402)
HIV-HBV
Coinfected 
(n = 61) P Value
Median age, y (IQR) 35 (30–41) 35 (29–39) .57
Female sex, n (10) 221 (55.0) 28 (45.9) .18
Body mass index, n (10)
 <18.5 44 (11.1) 9 (14.8) .26
 18.5–25 237 (59.6) 40 (65.6)
 >25 117 (29.4) 12 (19.7)
World Health Organization 
clinical stage 3 or 4, n (10)
191 (47.8) 27 (45.0) .69
Tuberculosis, n (10) 69 (17.2) 9 (14.8) .64
Hazardous alcohol  
consumption, n (10)
155 (39.0) 33 (55.0) .02
Hepatitis C virus coinfection, 
n (10)
0 0 NA
Median CD4+ count (IQR) 244 (130–338) 235 (111–382) .97
Median ALT, U/L (IQR) 18 (13–25) 23 (13–40) .02
Elevated ALT, n (10) 63 (19.6) 18 (30.5) .01
Median liver stiffness  
measurement, kPa (IQR)
5.0 (4.4–6.1) 5.5 (4.4–6.8) .04
HBV viral load (IU/mL), n (10)
 <20 12 (20.0)
 20–20 000 — 21 (34.4) —
 >20 000 27 (44.3)
HBV genotype, n (10) — —
 A (A1) 17 (43.6)
 E 22 (56.4)
Hepatitis B e antigen reactive, 
n (10)
— 18 (36.0) —
Hepatitis delta virus antibody 
positive, n (10)
— 2 (3.3) —
Abbreviations: ALT; alanine aminotransferase; HBV, hepatitis B virus; HIV, human immuno-
deficiency virus; IQR, interquartile range. 
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that ART was associated with reductions in liver fibrosis 
markers in those with only HIV and HIV–HBV coinfection. 
Improvement in liver fibrosis was also reported in patients 
with CHB [8] and HIV–HBV coinfection [25] who received 
TDF. Among 348 CHB patients in Europe, 176 (51%) had 
histological regression of fibrosis over 5 years of TDF [8]. 
In Ghana, over 3 years of TDF-containing ART, the propor-
tion of HIV monoinfected (30.8% to 21.8%) and HIV–HBV-
coinfected individuals (56.4% to 38.0%) with elevated LSM 
reduced significantly [3].
At 1 year, we observed that increasing age, male sex, and 
HBV coinfection were associated with persistently elevated 
LSM suggestive of significant fibrosis/cirrhosis. This is consist-
ent with other studies in the published literature. Increasing age 
and male sex have been shown to be potential cofactors for liver 
fibrosis progression [25, 26]. We did not find an association 
between hazardous drinking and TE at 1 year; however, quanti-
fying alcohol consumption by self-report alone can be difficult 
and is subject to underreporting [27]. Similar to our findings, 44 
of 76 (57.9%) HIV–HBV-coinfected Ghanaians had persistent 
elevations in LSM (>5.9 kPa) after switching from non-TDF to 
TDF-containing ART [24]. This may reflect that these patients 
have more severe liver disease before ART, incomplete HBV VS 
(as was observed in our study), or that TE measurements may 
be elevated by inflammation as well as fibrosis. We suspect that 
with additional follow-up, LSM will continue to improve in the 
setting of ART-treated HIV–HBV, as shown for CHB patients 
in China [9].
We also generated data on the short-term effectiveness 
of TDF-containing ART for HIV–HBV. Our finding that 
two-thirds of patients achieved HBV VS by 1  year is simi-
lar to findings from another study in the region and 1 in the 
United States [28, 29]. Longer follow-up of HBV VL may be 
needed to document full HBV VS. In a multicenter cohort of 
397 HIV–HBV patients in the United States, for example, the 
median time to HBV VS was 28 months (IQR, 13–71) [30]. In 
the Netherlands, the proportion of HBV-infected patients sup-
pressed on ART increased over time from 31% to 70% for those 
who were HBeAg positives and from 47% to 85% for those 
who were HBeAg negative [31]. In Zambia, we also demon-
strated an association between drug adherence and HBV VS, 
which is important not only in HIV–HBV coinfection but also 
in CHB. Although it was not observed in our study, HIV VS, 
another marker of adherence, predicted HBV VS among 133 
HIV–HBV patients on TDF-containing ART in the United 
States [29]. The rate of HBsAg loss (12.1%) we observed was 
higher than what has been listed in many reports from HIV–
HBV-coinfected and CHB patients in high-income countries 
[32–34] but similar to the 17.6% reported by Hamers et al [29] 
and lower than the 36% observed by Anderson et al [35]. Our 
rate of HBsAg loss may be slightly overestimated due to our use 
of a rapid test on whole blood that has lower sensitivity than 
serum assays [36].
Our study is one of the first in Africa to longitudinally 
assess hepatic stiffness using TE in HIV-infected individu-
als receiving ART and supports the general value of ART for 
liver health. These data also provide evidence in support of 
WHO recommendations for HBV-active ART for HIV–HBV-
coinfected patients. Our cohort had robust data on coinfec-
tions and comorbidities that may be liver disease cofactors. 
Because the study was nested within a public ART treatment 
program, we believe these data are likely to be representative 
of many HIV-infected and HIV–HBV-coinfected individuals 
in the region.
Table  2. Factors Associated With Significant Hepatic Fibrosis or 
Cirrhosis After 1 Year on Antiretroviral Therapy
Factor
Crude OR
(95% CI)
Adjusted OR
(95% CI)
Age, per 10-year increase 1.34 (0.92–1.96) 1.81 (1.07–3.07)
Sex
 Female Reference Reference
 Male 3.61 (1.58–8.26) 3.13 (1.10–8.93)
World Health Organization clinical stage
 1 or 2 Reference
 3 or 4 1.59 (0.76–3.33)
Body mass index
 <18.5 Reference
 18.5–25 2.10 (0.48–9.24)
 25+ 1.69 (0.34–8.22)
Hepatitis B virus coinfection 5.76 (2.66–12.50) 7.72 (2.89–20.57)
Tuberculosis 0.99 (0.39–2.49)
Hazardous alcohol consump-
tion at 1 year
1.75 (0.83–3.68)
CD4+ count at baseline, per 
50 cells/mm3 increase
1.03 (0.92–1.16)
Human immunodeficiency 
virus viral load <40 copies/ 
mL at 1 year
1.09 (0.35–3.37) 0.89 (0.26–3.04)
Abbreviations: CI, confidence interval; OR, odds ratio. 
Figure 3. Association between human immunodeficiency virus (HIV) and hepati-
tis B virus (HBV) viral suppression at 1 year on antiretroviral therapy among HIV–
HBV-coinfected adults. Abbreviation: HIV, human immunodeficiency virus.
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The main limitation of our study was incomplete serial TE 
data among approximately 30% of patients. Those with available 
data tended to be healthier and, as a consequence, we may have 
underestimated the prevalence of liver fibrosis in all patients 
starting ART. It is less likely that the analysis of risk factors for 
significant hepatic fibrosis or cirrhosis was affected by the miss-
ing data. Another limitation was our reliance on TE, which is 
a good but imperfect surrogate measure of liver fibrosis, and 
unlike newer versions, our TE device was not designed to assess 
steatosis. Time between TE measurements was only 1 year and, 
to some extent, observed changes may have reflected hepatic 
inflammation as well as fibrosis. Long-term follow-up is needed 
and will be pursued within our cohort. Additionally, more 
complete HIV VL data would have strengthened our ability to 
comment on HIV’s impact on liver inflammation and immune 
activation. We characterized a relatively small (n = 61) number 
of HIV-HBV patients, a key population at risk for cirrhosis and 
hepatocellular carcinoma (HCC) and acknowledge that more 
in-depth analysis of this group is warranted, including biannual 
screening for HCC. We also used a single positive HBsAg test 
at ART initiation to define HIV-HBV coinfection. Therefore, 
some patients with HBsAg loss at 1 year could have had acute 
HBV infection that did not progress to chronic infection. We 
think this is unlikely as only 1 of 10 patients with HBsAg loss 
had an elevated ALT at baseline consistent with acute infection.
In summary, initiation of TDF-containing ART was asso-
ciated with reduced liver fibrosis/cirrhosis in patients with 
HIV alone and HIV-HBV coinfection. Although the majority 
experienced HBV VS and reduction in LSM, many HIV–HBV-
coinfected patients had significant fibrosis/cirrhosis at 1 year on 
ART, suggesting the need for further follow-up and monitoring 
of this at-risk group.
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